Atezolizumab Effective in Late-Stage Non-Small-Cell Lung Cancer

Share this content:
Atezolizumab Effective in Late-Stage Non-Small-Cell Lung Cancer
Atezolizumab Effective in Late-Stage Non-Small-Cell Lung Cancer

TUESDAY, Dec. 13, 2016 (HealthDay News) -- The immunotherapy atezolizumab extends the survival of previously treated non-small-cell lung cancer patients for several months and causes fewer side effects than docetaxel, according to a study published online Dec. 12 in The Lancet.

The findings are from an early open-label analysis of 850 patients with squamous or non-squamous non-small-cell lung cancer in a phase 3 trial. The participants received either atezolizumab or docetaxel. Patients had previously received one to two cytotoxic chemotherapy regimens for stage IIIB or IV non-small-cell lung cancer.

According to a team led by David Gandara, M.D., of the University of California, Davis Comprehensive Cancer Center, patients who took atezolizumab survived for an average of 13.8 months, compared with 9.6 months for those on docetaxel. Patients taking atezolizumab also had lower rates of severe side effects. Fifteen percent experienced grade 3 or 4 adverse events while on atezolizumab, compared to 43 percent of those on docetaxel.

"This is the first phase 3 trial of a programmed death-ligand 1 [PD-L1]-directed immunotherapy in lung cancer," Gandara said in a journal news release. "The fact that it improves survival in patients with all categories of PD-L1 expression is highly encouraging and adds to the already known benefits of immunotherapy in lung cancer."

The study was funded by F. Hoffmann-La Roche and Genentech; Genentech is the manufacturer of atezolizumab.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »